{
  "id": 3213,
  "text": "Int J Gynecol Cancer 26, 722-728 (2016).1147.Gong, L., et al.Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.Int $J$ Gynaecol Obstet 117, 23-26 (2012).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Int J Gynecol Cancer 26, 722-728 (2016).1147.Gong, L., et al.Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.Int $J$ Gynaecol Obstet 117, 23-26 (2012).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "接受新辅助化疗（NACT）后进行根治性手术的IB2-IIB期宫颈癌患者，其临床效果通常表现为提高了肿瘤的切除率和病理缓解率。新辅助化疗能够使一些原本不适合手术的患者通过肿瘤缩小而获得手术机会，同时减少肿瘤周围浸润，增加R0切除（显微完全切除）的可能性。此外，研究显示，新辅助化疗结合根治性手术的治疗方式，有助于降低肿瘤扩散风险，尤其在淋巴结转移和周围组织浸润的控制方面效果较好，还可能提高特定患者的长期生存率。\n\n然而，这种治疗策略的成功率会受到原发肿瘤大小、患者身体状况以及对化疗方案的敏感性等因素的影响。因此，在选择治疗方案时，需结合患者具体情况进行评估，并权衡潜在风险与获益。长期随访数据建议，这种综合疗法在一些患者中可能改善总体及无病生存率，但仍需更多前瞻性研究以优化具体方案并验证其疗效。",
  "query": "对于接受新辅助化疗后进行根治性手术的IB2-IIB期宫颈癌患者，其临床效果如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 对于接受新辅助化疗后进行根治性手术的IB2-IIB期宫颈癌患者，其临床效果如何？\n\n<reference text>: Int J Gynecol Cancer 26, 722-728 (2016).1147.Gong, L., et al.Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.Int $J$ Gynaecol Obstet 117, 23-26 (2012).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "接受新辅助化疗（NACT）后进行根治性手术的IB2-IIB期宫颈癌患者，其临床效果通常表现为提高了肿瘤的切除率和病理缓解率。新辅助化疗能够使一些原本不适合手术的患者通过肿瘤缩小而获得手术机会，同时减少肿瘤周围浸润，增加R0切除（显微完全切除）的可能性。此外，研究显示，新辅助化疗结合根治性手术的治疗方式，有助于降低肿瘤扩散风险，尤其在淋巴结转移和周围组织浸润的控制方面效果较好，还可能提高特定患者的长期生存率。\n\n然而，这种治疗策略的成功率会受到原发肿瘤大小、患者身体状况以及对化疗方案的敏感性等因素的影响。因此，在选择治疗方案时，需结合患者具体情况进行评估，并权衡潜在风险与获益。长期随访数据建议，这种综合疗法在一些患者中可能改善总体及无病生存率，但仍需更多前瞻性研究以优化具体方案并验证其疗效。"
}